Real-world Experience with Decitabine Administered by a Non-Cytotoxic, DNMT1-Depleting Regimen in Patients with Myelodysplastic Syndromes

Authors :: Teodora Kuzmanovic
Cassandra M. Hirsch
Tomas Radivoyevitch
Hassan Awada
Bhumika J. Patel
Yogen Saunthararajah
Reda Z. Mahfouz
Jaroslaw P. Maciejewski
Source :: Clinical Lymphoma Myeloma and Leukemia. 18:S259-S260
Publication Year :: 2018
Publisher :: Elsevier BV, 2018.

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
business.industry
Myelodysplastic syndromes
Decitabine
Hematology
medicine.disease
Regimen
Internal medicine
DNMT1
medicine
Cytotoxic T cell
In patient
business
medicine.drug

Tools